Basal metabolic state governs AIF-dependent growth support in pancreatic cancer cells

• Published in: BMC cancer Vol. 16; no. 287; p. 286
• Main Authors: Scott, Andrew J, Wilkinson, Amanda S, Wilkinson, John C
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23-04-2016; BioMed Central
• Subjects: Analysis; Apoptosis - genetics; Apoptosis Inducing Factor - antagonists & inhibitors; Apoptosis Inducing Factor - biosynthesis; Apoptosis Inducing Factor - genetics; Apoptotic proteins; Carcinogenesis; Carcinogenesis - genetics; Cell Line, Tumor; Cell Proliferation - genetics; Cell Survival - genetics; Development and progression; Gene Expression Regulation, Neoplastic; Humans; Pancreatic cancer; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; RNA, Messenger - biosynthesis; Signal Transduction - genetics; Glycolysis; Mitochondria; Oxidative phosphorylation; Cell death
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-016-2320-3

Apoptosis-inducing factor (AIF), named for its involvement in cell death pathways, is a mitochondrial protein that regulates metabolic homeostasis. In addition to supporting the survival of healthy cells, AIF also plays a contributory role to the development of cancer through its enzymatic activity, and we have previously shown that AIF preferentially supports advanced-stage prostate cancer cells. Here we further evaluated the role of AIF in tumorigenesis by exploring its function in pancreatic cancer, a disease setting that most often presents at an advanced stage by the time of diagnosis.
A bioinformatics approach was first employed to investigate AIF mRNA transcript levels in pancreatic tumor specimens vs. normal tissues. AIF-deficient pancreatic cancer cell lines were then established via lentiviral infection. Immunoblot analysis was used to determine relative protein quantities within cells. Cell viability was measured by flow cytometry; in vitro and Matrigel™ growth/survival using Coulter™ counting and phase contrast microscopy; and glucose consumption in the absence and presence of Matrigel™ using spectrophotometric methods.
Archival gene expression data revealed a modest elevation of AIF transcript levels in subsets of pancreatic tumor specimens, suggesting a possible role in disease progression. AIF expression was then suppressed in a panel of five pancreatic cancer cell lines that display diverse metabolic phenotypes. AIF ablation selectively crippled the growth of cells in vitro in a manner that directly correlated with the loss of mitochondrial respiratory chain subunits and altered glucose metabolism, and these effects were exacerbated in the presence of Matrigel™ substrate. This suggests a critical metabolic role for AIF to pancreatic tumorigenesis, while the spectrum of sensitivities to AIF ablation depends on basal cellular metabolic phenotypes.
Altogether these data indicate that AIF supports the growth and survival of metabolically defined pancreatic cancer cells and that this metabolic function may derive from a novel mechanism so far undocumented in other cancer types.